ARCHIVES

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

This article is from The Cancer Letter archive.

Vol. 30 No. 42 | November 5, 2004

Download PDF Visit The Full Archive

Related Articles

NCI’s Justification For 1981 Budget

June 8, 1979

Continous Hormone Therapy Superior To Intermittent In 17-Year SWOG Study

June 29, 2012

Oklahoma Cancer Center Recruits Four Professors.

June 15, 2001

An Impromptu Group Proposes Standards For Publication Of Genomics Research

October 1, 2010

Ruffin Sworn In As Director, NIH Minority Health Center.

January 12, 2001

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

April 13, 2007